TAK Financials: Takeda Pharmaceutical Company Limited AI Analysis



Financials

TAK Financial

Takeda Pharmaceutical Company Limited

$18.17

-0.89%

$-0.16

As of today:Aug 20, 14:49:06 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$18.34

Open

$18.25

Day's Range

$18.15 - $18.34

52 week range

$12.99 - $18.9

Volume

1.2M

Avg.Volume

3.4M

Dividend yield

EPS (TTM)

-0.32

Market Cap

$58.0B

What is Takeda Pharmaceutical Company L?

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.

Features

Markets

News

Breakdown	TTM	06/30/2026	03/31/2026	12/31/2025	09/30/2025	06/30/2025
Revenue	4,618,935	1,219,900	1,094,541	1,191,698	1,112,796	1,106,685
Revenue Growth (YoY)	3%	10%	4%	4%	-5%	-8%
Cost of Revenue	1,593,589	406,676	405,704	401,148	380,061	384,675
Gross Profit	3,025,346	813,224	688,837	790,550	732,735	722,010
Selling, General & Admin	1,114,843	286,513	291,996	282,783	253,551	255,885
Research & Development	699,428	167,395	195,320	175,231	161,482	143,891
Operating Expenses	2,865,775	606,407	1,053,400	615,971	589,997	535,145
Other Non Operating Income (Expenses)	--	--	--	--	-1	1
Pretax Income	-130,267	162,718	-455,023	133,864	28,174	150,630
Income Tax Expense	32,881	49,462	-86,615	30,131	39,903	26,351
Net Income	-163,436	113,197	-368,471	103,640	-11,802	124,243
Net Income Growth	-219%	-9%	257%	336%	-112.99%	30%
Shares Outstanding (Diluted)	1,579.92	1,579.92	1,579.3	1,578.74	1,577.46	1,564.72
Shares Change (YoY)	1%	1%	0%	0%	-2%	-2%
EPS (Diluted)	-103.44	71.64	-233.31	65.64	-7.48	79.4
EPS Growth	-218%	-10%	257%	337%	-112.99%	32%
Free Cash Flow	514,530	24,387	11,239	153,501	325,403	140,355
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	65.49%	66.66%	62.93%	66.33%	65.84%	65.24%
Operating Margin	3.45%	16.95%	-33.3%	14.64%	12.82%	16.88%
Profit Margin	-3.53%	9.27%	-33.66%	8.69%	-1.06%	11.22%
Free Cash Flow Margin	11.13%	1.99%	1.02%	12.88%	29.24%	12.68%
EBITDA	862,104	369,859	-200,693	365,218	327,720	368,501
EBITDA Margin	18.66%	30.31%	-18.33%	30.64%	29.45%	33.29%
D&A For EBITDA	702,533	163,042	163,870	190,639	184,982	181,636
EBIT	159,571	206,817	-364,563	174,579	142,738	186,865
EBIT Margin	3.45%	16.95%	-33.3%	14.64%	12.82%	16.88%
Effective Tax Rate	-25.24%	30.39%	19.03%	22.5%	141.63%	17.49%

Breakdown

TTM

06/30/2026

03/31/2026

12/31/2025

09/30/2025

06/30/2025

Revenue

4,618,935

1,219,900

1,094,541

1,191,698

1,112,796

1,106,685

Revenue Growth (YoY)

10%

-5%

-8%

Cost of Revenue

1,593,589

406,676

405,704

401,148

380,061

384,675

Gross Profit

3,025,346

813,224

688,837

790,550

732,735

722,010

Selling, General & Admin

1,114,843

286,513

291,996

282,783

253,551

255,885

Research & Development

699,428

167,395

195,320

175,231

161,482

143,891

Operating Expenses

2,865,775

606,407

1,053,400

615,971

589,997

535,145

Other Non Operating Income (Expenses)

-1

Pretax Income

-130,267

162,718

-455,023

133,864

28,174

150,630

Income Tax Expense

32,881

49,462

-86,615

30,131

39,903

26,351

Net Income

-163,436

113,197

-368,471

103,640

-11,802

124,243

Net Income Growth

-219%

-9%

257%

336%

-112.99%

30%

Shares Outstanding (Diluted)

1,579.92

1,579.3

1,578.74

1,577.46

1,564.72

Shares Change (YoY)

-2%

EPS (Diluted)

-103.44

71.64

-233.31

65.64

-7.48

79.4

EPS Growth

-218%

-10%

257%

337%

-112.99%

32%

Free Cash Flow

514,530

24,387

11,239

153,501

325,403

140,355

Free Cash Flow Per Share

Gross Margin

65.49%

66.66%

62.93%

66.33%

65.84%

65.24%

Operating Margin

3.45%

16.95%

-33.3%

14.64%

12.82%

16.88%

Profit Margin

-3.53%

9.27%

-33.66%

8.69%

-1.06%

11.22%

Free Cash Flow Margin

11.13%

1.99%

1.02%

12.88%

29.24%

12.68%

EBITDA

862,104

369,859

-200,693

365,218

327,720

368,501

EBITDA Margin

18.66%

30.31%

-18.33%

30.64%

29.45%

33.29%

D&A For EBITDA

702,533

163,042

163,870

190,639

184,982

181,636

EBIT

159,571

206,817

-364,563

174,579

142,738

186,865

EBIT Margin

3.45%

16.95%

-33.3%

14.64%

12.82%

16.88%

Effective Tax Rate

-25.24%

30.39%

19.03%

22.5%

141.63%

17.49%

Follow-Up Questions

What are Takeda Pharmaceutical Company Limited's key financial statements?



According to the latest financial statement (Form-10K), Takeda Pharmaceutical Company Limited has a total asset of $0, Net loss of $0

What are the key financial ratios for TAK?



Takeda Pharmaceutical Company Limited's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Takeda Pharmaceutical Company Limited's revenue broken down by segment or geography?



Takeda Pharmaceutical Company Limited largest revenue segment is Gastroenterology Revenue (Pre-FY2023 Reporting), at a revenue of 1,216,207,000,000 in the most earnings release.For geography, Japan is the primary market for Takeda Pharmaceutical Company Limited, at a revenue of 433,110,000,000.

Is Takeda Pharmaceutical Company Limited profitable?



no, according to the latest financial statements, Takeda Pharmaceutical Company Limited has a net loss of $0

Does Takeda Pharmaceutical Company Limited have any liabilities?



no, Takeda Pharmaceutical Company Limited has liability of 0

How many outstanding shares for Takeda Pharmaceutical Company Limited?



Takeda Pharmaceutical Company Limited has a total outstanding shares of 0

Takeda Pharmaceutical Company Limited (TAK) Financial

TAK Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Takeda Pharmaceutical Company L?

Takeda Pharmaceutical Company Limited (TAK) Financial

TAK Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Takeda Pharmaceutical Company L?

TAK Income

Follow-Up Questions

What are Takeda Pharmaceutical Company Limited's key financial statements?

What are the key financial ratios for TAK?

How is Takeda Pharmaceutical Company Limited's revenue broken down by segment or geography?

Is Takeda Pharmaceutical Company Limited profitable?

Does Takeda Pharmaceutical Company Limited have any liabilities?

How many outstanding shares for Takeda Pharmaceutical Company Limited?